CATANIA, Italy, Nov. 19, 2020 /PRNewswire/ -- SIFI, a leading ophthalmic company, announced today that it has achieved the full enrollment of 135 patients with Acanthamoeba keratitis (AK) in its ...

The European Commission has approved SIFI's Akantior as the first therapy anywhere in the world for acanthamoeba keratitis (AK), an ultra-rare parasitic infection that can lead to blindness. Akantior ...

The CHMP recommendation will now be reviewed by the European Commission (EC), which may decide on the marketing authorisation (MA) for AKANTIOR ® in August 2024. The decision will then be applicable ...

European Medicines Agency: Received AKANTIOR ® Trade Name approval; Conducted favourable pre-Marketing Authorisation Applications meetings with designated Rapporteurs; Reiterated original guidance to ...

CATANIA, Italy, Sept. 30, 2024 /PRNewswire/ -- SIFI, a leading international ophthalmic company, announced that is has received a Notice of Allowance from the European Patent Office ("EPO") for ...

Polihexanide 0.08% Exhibits Compelling Safety and Tolerability Characteristics in Healthy Volunteers CATANIA, Italy, Feb. 1, 2021 /PRNewswire/ -- SIFI, a leading ophthalmic company, announced today ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved polihexanide (Akantior) to treat acanthamoeba keratitis. Acanthamoeba keratitis is an infection of the cornea, the clear ...

The study topline results expected in the second half of 2021 CATANIA, Italy, Nov. 19, 2020 /PRNewswire/ -- SIFI, a leading ophthalmic company, announced today that it has achieved the full enrollment ...

The company's intellectual property ("IP") covers the formulation and method of use of polihexanide in the treatment of acanthamoeba keratitis and fungal keratitis The patent, already granted in Italy ...

CATANIA, Italy, Nov. 19, 2020 /CNW/ -- SIFI, a leading ophthalmic company, announced today that it has achieved the full enrollment of 135 patients with Acanthamoeba keratitis (AK) in its pivotal ...